


Mezigdomide

Cat. No.:	HY-129395		
CAS No.:	2259648-80-9		
Molecular Formula:	C ₃₂ H ₃₀ FN ₅ O ₄		
Molecular Weight:	567.61		
Target:	E1/E2/E3 Enzyme; Apoptosis; Molecular Glues		
Pathway:	Metabolic Enzyme/Protease; Apoptosis; PROTAC		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 5 mg/mL (8.81 mM; ultrasonic and warming and heat to 60°C)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	1.7618 mL	8.8089 mL	17.6177 mL
5 mM	0.3524 mL	1.7618 mL	3.5235 mL
10 mM	---	---	---

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Mezigdomide (CC-92480), a cereblon E3 ubiquitin ligase modulating agent (CELMoD), acts as a molecular glue. Mezigdomide shows high affinity to cereblon, resulting in potent antimyeloma activity^[1].

In Vitro

Mezigdomide is the second cereblon modulator. Mezigdomide-induced loss of Aiolos and Ikaros in cultures of PBMCs resulted in the activation of T cells and increased production of IL-2 and IFN-γ. Mezigdomide is effective in CC-5013, CC-4047, and CC-220-resistant cell lines. It exerts single-agent induction of apoptosis and exhibits remarkable synergy with NSC 34521^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Nooka AK, et al. Mechanism of Action and Novel IMiD-Based Compounds and Combinations in Multiple Myeloma. Cancer J. 2019 Jan/Feb;25(1):19-31.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA